South Korea approves its first homemade Covid vaccine for people aged above 18

Vaccine appreared to be more effective than AstraZeneca in generating immune response in trials

<p>File photo: People receive the first dose of the Pfizer-BioNTech Covid-19 coronavirus vaccine at a vaccination center in Seoul on 28 July</p>

File photo: People receive the first dose of the Pfizer-BioNTech Covid-19 coronavirus vaccine at a vaccination center in Seoul on 28 July

The South Korean government has approved the country’s first indigenous Covid-19 vaccine for people aged 18 and above in a major step towards vaccine sovereignty in Seoul’s fight against the pandemic.

The two-dose SKYCovione vaccine, developed by SK Bioscience, was approved after it successfully completed all three phases of its clinical trial and appeared to be more effective than AstraZeneca jabs, according to officials at the country’s Food and Drug Safety Ministry.

The third phase of trial was conducted in Thailand, Vietnam, New Zealand, Ukraine, the Philippines and South Korea.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in